Company: SXTPW
Filing Date: 2025-08-27
Form Type: DEF 14A
Source: 0001213900-25-080878
Chunk: 16

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-08-27
Form: DEF 14A
Chunk 16
---
                                        |     | July 12, 2023 |     | Audit – Chairman; Compensation; Nominating and Corporate Governance. |
| Cheryl Xu      |     |  57 |     | Director                                        |     | July 12, 2023 |     | None                                                                 |
| Stephen Toovey |     |  71 |     | Director                                        |     | July 12, 2023 |     | Nominating and Corporate Governance – Chairman; Compensation; Audit. |
| Paul Field     |     |  62 |     | Director                                        |     | July 12, 2023 |     | Compensation – Chairman; Audit; Nominating and Corporate Governance. |

Geoffrey Dowis our Chief Executive
Officer, President, and is also one of our directors. Dr. Dow has over 20 years of product development experience in tropical diseases
and has an extensive publication and patent history. His decades of hands-on experience include 13 years in key leadership and advisory
roles in the antimalarial drug development program at the Walter Reed Army Institute of Research and at the U.S. Army Medical Materiel
Development Activity. Dr. Dow co-founded 60P in 2010. Since then, he has been involved in various projects, including leading the project
development team in securing FDA-regulatory approval for Tafenoquine (as Arakoda) for malaria prophylaxis, securing a supply chain and
access relating to Arakoda, managing post-marketing regulatory commitments, ensuring the successful prosecution of supporting patents
on which Dr. Dow was an inventor, and ensuring the company adheres to GMP, quality, and pharmacovigilance requirements. Dr. Dow has also
published a number of important safety reviews, clinical trials, non-clinical studies, on which he was a thought leader or contributor,
which dispelled many of the myths about 8-aminoquinolines. As a scientist, experienced industry project manager and inventor, Dr. Dow’s
ultimate goal is to develop and secure the regulatory approval and commercial success of products, old and new, for new indications in
infectious disease. Dr. Dow received a B.Sc. (Hons) in Veterinary and Biomedical Science from Murdoch University, Perth, Western Australia
(“Murdoch”) in 1994, a Ph.D. in Veterinary and Biomedical Science from Murdoch in 2000 and an MBA from the University of Maryland
at College Park in 201